Moderna asks FDA to authorize its updated Covid booster shot
Moderna asked the Food and Drug Administration to authorize its bivalent omicron Covid booster.
Moderna said Tuesday it had asked the Food and Drug Administration to authorize an updated version of its Covid booster shot that targets the highly contagious BA.5 omicron subvariant.
The drugmaker’s application to the FDA, which covers adults ages 18 and older, follows a similar request from Pfizer-BioNTech on Monday. Pfizer is seeking authorization for everyone 12 and older.
Like Pfizer’s updated booster, Moderna’s so-called bivalent vaccine is specifically designed to target omicron subvariants, BA.4 and BA.5, as well as the original coronavirus strain in a single shot. The move follows a recommendation from the FDA in June to modify the vaccines to target the two subvariants.
Full coverage of the Covid-19 pandemic
BA.5, in particular, is responsible for nearly 90% of all new Covid cases in the United States, according to data from the Centers for Disease Control and Prevention.
Rating: 5